Efalizumab
Based on 1 publication(s) in Google Scholar
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.00%
- CAS No.: 214745-43-4
- Masse moléculaire:146.238 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-19344
LifitegrastLFA-1/ICAM-1 Antagonist -
HY-P99336
EnlimomabAnti-ICAM-1 Antibody -
HY-108831
NatalizumabAnti-α4 Integrin Monoclonal Antibody -
HY-108738
DaclizumabCD25 Blocker -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-10219
RapamycinmTOR Inhibitor -
HY-P9906
BevacizumabVEGF-A Inhibitor -
HY-P9913
RituximabCD20 Inhibitor -
HY-108810
CanakinumabAnti-IL-1β Monoclonal Antibody -
HY-P9922
OlaratumabAnti-PDGFRα Antibody -
HY-108852
BasiliximabAnti-IL-2R mAb -
HY-110117
BIRT 377LFA-1 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Efalizumab
More
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD11a/LFA-1α
In Vitro
Efalizumab (78 ng/mL-5 mg/mL) induces a leukocytosis and downregulates LFA-1 expression on T cells in the peripheral blood[3].
Efalizumab (78 ng/mL-5 mg/mL) downregulates plate-bound, anti-CD3-stimulated proliferation of PBMC[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 214745-43-4
-
Appearance Liquid
-
Masse moléculaire 146.238 kDa
-
Color Colorless to light yellow
-
SMILES
[Efalizumab]
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S98-104. [Content Brief]
[2]. Berger JR, et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009 Nov-Dec;1(6):583-9. [Content Brief]
[3]. Koszik F, et al. Efalizumab modulates T cell function both in vivo and in vitro. J Dermatol Sci. 2010 Dec;60(3):159-66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Efalizumab Related Classifications
HY-P9947 Related Classifications
Powered by Bioz